Celon Pharma SA (CLN) - Total Liabilities

Latest as of March 2026: zł141.95 Million PLN ≈ $39.07 Million USD

Based on the latest financial reports, Celon Pharma SA (CLN) has total liabilities worth zł141.95 Million PLN (≈ $39.07 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Celon Pharma SA to evaluate the company's liquid asset resilience ratio.

Celon Pharma SA - Total Liabilities Trend (2012–2025)

This chart illustrates how Celon Pharma SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CLN total assets.

Celon Pharma SA Competitors by Total Liabilities

The table below lists competitors of Celon Pharma SA ranked by their total liabilities.

Company	Country	Total Liabilities
EMS Limited NSE:EMSLIMITED	India	Rs2.72 Billion
EBEST Investment & Securities Co. Ltd KQ:078020	Korea	₩13.22 Trillion
Kardan Israel Ltd TA:KRDI	Israel	ILA2.33 Billion
Settlebank Corporation KQ:234340	Korea	₩343.70 Billion
Arman Financial Services Limited NSE:ARMANFIN	India	Rs18.64 Billion
W-SCOPE CHUNGJU PLANT LTD (PROPOSE KQ:393890	Korea	₩1.09 Trillion
ITHAX Acquisition Corp III Class A Ordinary Shares NASDAQ:ITHA	USA	$43.54K
BAIC Motor Corp Ltd F:2B5	Germany	€89.42 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Celon Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Celon Pharma SA to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.20	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.27	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.21	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Celon Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Celon Pharma SA (2012–2025)

The table below shows the annual total liabilities of Celon Pharma SA from 2012 to 2025.

Year	Total Liabilities	Change
2025-12-31	zł74.47 Million ≈ $20.49 Million	-24.47%
2024-12-31	zł98.59 Million ≈ $27.13 Million	-20.33%
2023-12-31	zł123.75 Million ≈ $34.06 Million	-4.28%
2022-12-31	zł129.29 Million ≈ $35.58 Million	-15.57%
2021-12-31	zł153.14 Million ≈ $42.15 Million	-43.07%
2020-12-31	zł268.97 Million ≈ $74.02 Million	+83.84%
2019-12-31	zł146.31 Million ≈ $40.27 Million	+27.29%
2018-12-31	zł114.94 Million ≈ $31.63 Million	+34.90%
2017-12-31	zł85.20 Million ≈ $23.45 Million	+37.82%
2016-12-31	zł61.82 Million ≈ $17.01 Million	-8.38%
2015-12-31	zł67.47 Million ≈ $18.57 Million	+88.38%
2014-12-31	zł35.82 Million ≈ $9.86 Million	+17.86%
2013-12-31	zł30.39 Million ≈ $8.36 Million	+113.63%
2012-12-31	zł14.22 Million ≈ $3.91 Million	--

About Celon Pharma SA

WAR:CLN Poland Drug Manufacturers - Specialty & Generic

Market Cap

$231.31 Million

zł840.49 Million PLN

Market Cap Rank

#16113 Global

#105 in Poland

Share Price

zł21.60

Change (1 day)

-2.48%

52-Week Range

zł18.82 - zł23.50

All Time High

zł51.09